hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
== Classification == This mushroom has been placed in the section Aztecorum by Gaston Guzman; other members of the section include Psilocybe aztecorum var. aztecorum, Psilocybe aztecorum var. bonetii, Psilocybe pseudoaztecorum, and Psilocybe quebecensis.
=== 2000 === 13 March The Secret Life of the Crash Test Dummy, about the biomechanics of car crashes; a typical crash test dummy cost around £100,000, with about three hundred individual parts, that had to be included by safety law, and new cars could not be sold until the dummy had tested it sufficiently; the Volvo 300 1980s television advert; Lt-Col Wayne Mattson of the USAF and a strange crash in New Mexico, one hundred miles north of the Trinity (nuclear test), and near White Sands Missile Range, where German V-2 missiles were being tested, which were conveniently blamed by the USAF on anthropomorphic dummies; John Melvin (engineer) and the legacy of USAF biophysicist and doctor Colonel John Stapp, who mostly invented aviation safety testing; John Stapp conducted gruesome horrific deceleration tests on himself; Alderson had made artificial limbs for injured USAF World War II pilots, so made a full artificial proto-human; John Stapp tested his dummies in vehicles; Clarence Ditlow and the Center for Auto Safety; in 1966 it became legal in the US for new cars to have been tested by dummies; mathematical models of injury were needed, to translate the acquired crash data into possible effects on the human body, worked out by mechanical engineer Walter Pilkey of the University of Virginia; Scottish orthopaedic surgeon Angus Wallace and impact speed on bone tensile strength; in 1976 the Hybrid III dummy was designed, the automotive industry standard design; David Abbott, advertising executive; the data for designing the crash test dummy, Hybrid III, was mostly derived from data procured for human male occupants - and typical (fiftieth percentile) males, not female, and females had much different bodies; child dummies were essentially smaller adult male dummies, which was not biologically true; new dummies were developed at the National Transportation Biomechanics Research Center. Narrated by Andrew Lincoln, produced by Cathy Rogers, directed by Peter Webber, made by RDF Television. Shown on Wednesday 17 January 2001 on The Nature of Things in Canada 20 March Rise and Fall of GM Food, about genetically modified food; Belgian geneticist Marc Van Montagu, of the University of Ghent, visits Havana in Cuba, where a new research centre opened with Carlos Borroto; protests by topless women; GM was largely first developed by Mexican geneticist Herrera Estrella, of the Centre of Investigation and Advanced Studies; Rob Fraley of Monsanto; US farmers spend $8bn dollars on herbicides and pesticides; Roger N. Beachy had a breakthrough in 1986 at the Washington University in St. Louis, now at the Donald Danforth Plant and Science Center; Monsanto made the first insecticide-resistant plant in 1987; many African farmers cannot afford insecticides; Cyrus Ndiritu of the Kenya Agriculture Research Institute; much food harvested in Africa does not last before it reaches the consumer; in 1990 Don Grierson of the Plant Science Division of the University of Nottingham found genes of ripening; Channapatna Prakash of Tuskegee University in Alabama; aluminium toxicity of soils in tropical countries affected yield; Julian Borger of The Guardian; biologist Mae-Wan Ho of the Open University; biologist John Gatehouse of the University of Durham, and the Pusztai affair at The Rowett Institute; Helen Browning, Chairman of the Soil Association; former Vice-Chancellor of UEA, Derek Burke; former Independent environment correspondent Richard D. North, who had grown out of love with the hard-line environmental movement; European farmers grew five times more produce than they did in the 1960s, and there were twice as many trees in the UK than in the 1920s; Renée Elliott of Planet Organic; around 100m children in Third World countries suffered from Vitamin A deficiency. Directed by Martin Durkin, made by his company Kugelblitz 27 March Simply Complex, about the physicist Murray Gell-Mann; by an accident, he devised strangeness of sub-atomic particles, in his mid-20s; he predicts an omega minus particle, which was found in 1962; he predicts that the proton and neutron were made of three triplet particles, which he called quarks from Finnegans Wake and his Eightfold way (physics), also predicted by George Zweig; he worked closely with Richard Feynman at Caltech in the 1960s; on 30 October 1969 he is told that he had won the Nobel Prize for Physics; his friendship with MIT mechanical engineer Seth Lloyd; British physicist Geoffrey West; the documentary is in a biographic informal style that Horizon has since often followed. Produced by Barbara Altounyan, directed by Celia Lowenstein, made by Diverse Productions 3 April Meningitis - Search for a Cure, 3,000 people in the UK had meningitis in 1999; microbiologist Martin C. J. Maiden; one in five died from meningococcal disease; damage is caused by the endotoxin (lipopolysaccharide); a healthy survey is carried out at Burford School; Mike Levin (paediatrician) at Imperial College, and how meningitis A is a huge danger in Africa; 60% of cases in the UK are meningitis B, and many such cases are treated at St Mary's Hospital, London; Brett Giroir of the Children's Medical Center Dallas; 17-year-old Amy Mansell from Whitstable was in a coma for five weeks. Narrated by Paul Brightwell, produced by David Dugan, directed by Jeremy Llewellyn-Jones, made by Windfall Films with Nova and WGBH Boston. It was shown on Nova as Killer Disease on Campus, episode 9 of season 29, shown on 3 September 2002, and shown under the original programme title as a half-hour programme on 6 November 2003 on Catalyst on ABC in Australia 10 April The Box, about flight recorders, with ValuJet Airlines Flight 592 which crashed on 11 May 1996; voice recorders have been compulsory since the late 1960s; Dukane Seacom make emergency underwater locator beacons (ULBs); the Boeing 737, which had around 21,000 take-offs per day, was believed to have unreliable rudder control since the 1980s, as shown in the United Airlines Flight 585 crash on 3 March 1991, having had two rudder incidents in the previous two weeks, with the aircraft flipping 35 seconds after take-off and crashing all in seven seconds; the electrohydraulic servo valve in the Boeing 737 rudder control unit was thought to be sometimes temperamental; Boeing claimed that the March 1991 crash was due to a rotor or lee wave, caused by nearby mountains; the USAir Flight 427 crash on 8 September 1994, where the aircraft flipped at 6,000 ft, in 28 seconds crashing; British Airways did not rely on their Penny & Giles quick access recorders, and would consolidate this data where anomalies were checked, so the NTSB needed BA's data for their 737 aircraft; this safer BA method was introduced by the previous British European Airways (BEA) when it had to prove to the CAA that its autoland system for the Trident was safe, in the Civil Aircraft Airworthiness Data Recording Programme which since 1990 has been collected by the British Airways Safety Information System (BASIS); the 1991 crash investigation concluded after 8 years in 1999, with Boeing ordered to redesign the servo valve. 9 October Full Throttle, about the technology and psychology of motor racing; Brazilian driver Christian Fittipaldi; the Eurofighter, controlled by computers, and due to enter RAF service in 2002; Archie Neill, BAE test pilot; Stephen Olvey, motor racing medical officer; driver Mark Blundell; the Long Beach Grand Prix in Los Angeles; Steve Clark, engineer for Mercedes; Brian Lisles and Peter Gibbons of Newman Haas Racing; the edge of performance envelope; Mario Andretti, former driver: Edward Winter of Sheffield Hallam University and predicting outcomes in sport, by intuition; John Rothwell of the Institute of Neurology in London, testing reflexes, by an MRI scanner, and how the brain stores instructions; psychologist Mike Land of the University of Sussex, and the psychology of prediction, and feedforward; life expectancy of racing drivers in the 1970s was short; racing drivers had risk positive personalities, and became accustomed to risk; psychologist Tim Wheeler; Jimmy Vasser of Chip Ganassi Racing; a female violinist plays La fille aux cheveux de lin; sports psychologist Brian Hemmings; Austrian driver Alexander Wurz of Benetton Formula; RAF SEPECAT Jaguar XZ103 of 41 Squadron; engineer Pat Symonds of Benetton Racing; Simon Taylor (journalist) of Motor Sport; Graham Rood of DERA Air Systems in north Hampshire. Narrated by Stephen Rashbrook, produced by Patrick Uden, directed by Andy Robbins, made by Uden Associates 16 October Lethal Seas: the Maelstrom, about ocean whirlpools; the Gulf of Corryvreckan in Scotland, Lofoten and Saltstraumen in Norway; with Prof Tsukasa Nishimura of Tokyo University of Science and Prof Walter Munk of the Scripps Institution of Oceanography; the Firth of Lorn in west Scotland has one of the world's most dangerous whirlpools, the Royal Navy avoids it; atmospheric physicist Peter Read; mathematician David Dritschel, and the Great Red Spot vortice; the dangerous Arran Rapids on the Cordero Channel in western Canada; Burkard Baschek of the Institute of Ocean Sciences, who dropped a CTD (instrument) into the torrential river currents; Tremble Island in the notorious Slingsby Channel, where a geophone was placed; the novel A Descent into the Maelström; Bjørn Gjevik, a fluid dynamicist in the Department of Mathematics, at the University of Oslo; strong tidal currents in the Naruto Strait in Japan, and the Naruto whirlpools. Narrated by Stephen Rashbrook, produced by Robert Sproul-Cran, directed by Kim Flitcroft, made by Northlight Productions with the Discovery Channel 23 October Einstein's Biggest Blunder, about calculations of the expansion of the universe; the documentary opens with a pastiche of the Star Wars opening credits; two physicists met in 1996, with a new radical proposal for explaining the many anomalies in the expansion of the universe - Andreas Albrecht (cosmologist) of the University of California, Davis and João Magueijo of Portugal; Dave Wark of the University of Sussex, visits Bern in Switzerland; Ruth Durrer of the University of Geneva; John E. Baldwin of the University of Cambridge, and the 1887 Michelson–Morley experiment, which found that the Earth's rotational speed did not affect the speed of light in any way, alongside the Venus movement of The Planets; to account for this, Einstein made his field equations, and lambda - the cosmological constant was added by Einstein to account for how space-time would need to expand; Einstein's equations inferred that the expansion of the universe rested on inherently unstable conditions; due to the Doppler effect, background radiation from the Big Bang is now perceived as microwave radiation; Richard Ellis (astronomer) of Caltech; Einstein didn't believe in the Big Bang until a meeting with Hubble in 1932 in California; with the new theory of an expanding universe, the cosmological constant was now required, but the precise trajectory of the expansion of the universe could not be directly predicted, which led to the flatness problem; the theory of inflation was put forward by Alan Guth in the 1970s; when at St John's College, Cambridge, João Magueijo had the radical proposal that if the speed of light was higher, in the early universe, a cosmological horizon of sufficient distance would be possible, to explain the predicted conditions of the expansion of the early universe, and the cosmological constant problem; the Royal Society gave him a research fellowship to work at Imperial College; as further exploratory work was clocked up, with calculations inclya variable speed of light, the team of physicists looked at other applications for their controversial proposals, such as the flatness problem, and what happened before the Big Bang; in 1998 astrophysicist John Webb, at the University of Cambridge, worked on the theory of a variable speed of light, through investigating quasars, the most distant objects that can be seen; and by looking at supernovae, it was largely expected that any recorded data would show indications of a deceleration in the rate of expansion of the universe, but the data instead showed that the rate of expansion was - increasing, which led to the lambda-CDM model. Narrated by Scottish actor Matthew Zajac, directed by David Sington, made by Dox Productions 30 October The Science of Stress, with 42-year-old actor Angus Kennedy; endocrinologist Stafford Lightman of the University of Bristol; Vivette Glover, a perinatal psychobiological at Imperial College; Sir Cary Cooper, psychologist at the former UMIST; Carolyn M. Mazure, psychiatrist at Yale School of Medicine; Charles Nemeroff, psychiatrist at Emory University School of Medicine. Narrated by Geoffrey Palmer, directed by Michael Samuels, produced by Bridget Sneyd, made by Lion Television and the Discovery Health Channel 7 December Science of Crime - Psychopath, with psychologists Robert D. Hare and Adrian Raine, about the psychopathic traits of insincere superficial charm, on the Psychopathy Checklist. Narrated by Neil Pearson, directed by John Purdie, produced by Rosalind Arden, made by Union Pictures 14 December Science of Crime - Criminal Evidence, about the forensic psychologist 49-year-old Kathy Reichs. Produced by Geoff Deehan, directed by Roger Pyke, made by Yap Films 21 December Science of Crime - Cybercops, the Hackers on Planet Earth conference; Cult of the Dead Cow, founded by Swamp Rat, and its Back Orifice software for accessing Windows 98; the Happy99 virus; wardialing; part of the High Technology Theft Apprehension and Prosecution Program in California. Narrated by Steven Mackintosh, written by Callum Macrae, directed by Witold Starecki
identify metabolic disease signatures assess treatment class (pre- or post-treatment) identify compounds present in a patient sample that may alter drug response, or be caused by a therapy identify metabolite variables and interactions among these variables map identified variables to known metabolic and biochemical pathways
=== Progestogenic activity === CPA is a highly potent progestogen. It is described as the most potent progestin of the 17α-hydroxyprogesterone group, being about 1,200-fold more potent than hydroxyprogesterone acetate, 12-fold more potent than medroxyprogesterone acetate, and 3-fold more potent than chlormadinone acetate in animal bioassays. Based on results in the animal bioassays, CPA has also been said to be the most potent progestin known, with 1,000 times the potency of progesterone. With oral administration in humans however, CPA is distinctly less potent as a progestogen than various other progestins such as the 19-nortestosterone derivatives. The effective dosage of CPA needed to inhibit ovulation by itself in women (i.e., to act as a contraceptive) is 1 mg/day, and the medication is marketed as a contraceptive (combined with low-dose ethinylestradiol) at a dosage of 2 mg/day. For comparison, the ovulation-inhibiting dosage of levonorgestrel is 50 μg/day. At the dosages typically used clinically, CPA is described as a "strong" and "powerful" progestogen. Its endometrial transformation dosage is 20 to 30 mg per cycle and its menstrual delay test dosage has been estimated to be less than 1 mg/day. CPA is not well-balanced in terms of its activities; relative to the progestogenic potency of CPA, its potency as an androgen receptor antagonist is quite weak. In order to take full advantage of its antiandrogenic activity, CPA must be administered at a dosage of 50 to 100 mg per day, which is 2 to 3 times the cyclical endometrial transformation dose per day.
== Medical career == Coatsworth is a Fellow of the Royal Australasian College of Physicians. His specialties are respiratory medicine and infectious diseases. He is currently director of infectious diseases at Canberra Hospital. His other roles have included executive director at the National Critical Care and Trauma Response Centre in Darwin. He has also lectured in medicine at the Australian National University. Coatsworth led humanitarian teams in the Congo and the Darfur region of Sudan for Medicins Sans Frontiers when he was 25, a task that he says left him with PTSD. He told the Today programme: "I think everyone has their limits in life and I kind of reached that, the security situation there was really difficult. There was the threat of assassination of people in the place where we were." After returning home, Coatsworth became anxious: "I felt like I was having these heart palpitations ... At the end of 2019 it got to the point one weekend I couldn't leave the house." He took anxiety medication to resolve the issue. He was elected to the board of Medicins Sans Frontiers in Australia in 2008. He served as the board's president in 2010 and 2011. He also led the second Australian Medical Assistance Team to the Philippines after Typhoon Haiyan in 2013. His other deployments with the Australian Medical Assistance Team include Vanuatu after Cyclone Pam in 2015 and Fiji following Cyclone Winston in 2016. In 2023, Coatsworth joined Patients Australia as Ambassador for Health Reform.
Sources: en.wikipedia.org
The researcher found that, in this case, reverse phase HPLC, was a better, more sensitive technique despite the time savings in direct injection. Analysis of pharmaceuticals by MLC is also gaining popularity. The selectivity and peak shape of MLC over commonly used ion-pair chromatography is much enhanced. MLC mimics, yet enhances, the selectivity offered by ion-pairing reagents for the separation of active ingredients in pharmaceutical drugs. For basic drugs, MLC improves the excessive peak tailing frequently observed in ion-pairing. Hydrophilic drugs are often unretained using conventional HPLC, are retained by MLC due to solubilization into the micelles. Commonly found drugs in cold medications such as acetaminophen, L-ascorbic acid, phenylpropanolamine HCL, tipepidine hibenzate, and chlorpheniramine maleate have been successfully separated with good peak shape using MLC. Additional basic drugs like many narcotics, such as codeine and morphine, have also been successfully separated using MLC. Another novel application of MLC involves the separation and analysis of inorganic compounds, mostly simple ions. This is a relatively new area for MLC, but has seen some promising results. MLC has been observed to provide better selectivity of inorganic ions that ion-exchange or ion-pairing chromatography. While this application is still in the beginning stages of development, the possibilities exist for novel, much enhanced separations of inorganic species. Since the technique was first reported on in 1980, micellar liquid chromatography has been used in hundreds of applications.
The acute and chronic inflammatory processes of osteoradionecrosis are prevented by the administration of steroidal anti-inflammatory drugs. In addition, the administration of pentoxifylline and antioxidant treatments, such as superoxide dismutase and tocopherol (vitamin E) are recommended.
Mass cytometry is a high-dimensional single-cell analysis technique that integrates flow cytometry with time of flight mass spectrometry. It is used for the determination of the properties of cells (cytometry). In this approach, antibodies are conjugated with isotopically pure elements, and these antibodies are used to label cellular proteins. Cells are nebulized and sent through an argon plasma, which ionizes the metal-conjugated antibodies. The metal signals are then analyzed by a time-of-flight mass spectrometer. The approach overcomes limitations of spectral overlap in flow cytometry by utilizing discrete isotopes as a reporter system instead of traditional fluorophores which have broad emission spectra.
== Economic significance == In 2024, South Africa's logistics sector contributed R518.4 billion towards the country's GDP, a year-over-year increase of 4.3%. South Africa's logistics sector is expected to grow at a CAGR of 9.1% from 2026 to 2033. In 2025, the country accounted for 2.3% of the global logistics market. In 2026, South Africa's logistics sector was growing the fastest out of all countries in the Middle East & Africa region. Examples from Wesgro of the South African logistics sector's impact on the country's economy as a whole are in the table below.
=== Max Braverman === Max Braverman (Max Burkholder) is Adam and Kristina's son (age 8 in the series pilot episode, although he is 14 in season 5) who is diagnosed with Asperger's syndrome at the beginning of the first season. His struggles and triumphs with this syndrome affect much of what happens in his family. Max is unaware of his diagnosis in the early episodes (although he is enthusiastic about participating in a "Walk for Autism"), but during the second season he learns about it after witnessing an argument between Adam and Crosby. His parents decide to transfer him to a mainstream school after being told that Max is very intelligent. In the season 2 finale, while at the hospital Max becomes very angry, saying that he wants pancakes more than he cares about Amber, even going as far as saying that doesn't care about her. Adam scolds Max for his hurtful comments, but Max believes he didn't do anything wrong, though at the end he apologizes to Sarah for what he said. In season 3, Max has been mainstreamed into a normal school, to challenge him academically. He is trying hard to make friends, though it proves difficult. He does make a friend in season 3, a boy with spina bifida named Micah, whose parents are thrilled because, like Max, he's never had a friend before. It is also discovered that Max is academically gifted. Though socially behind others his age, he is academically far above most others his age and older. In the fourth season, he is elected class president of Cedar Knoll Middle School with some help from his older sister Haddie.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.